EMA Approves Tx for Psoriasis and Other Autoimmune Disorders
The biosimilar Pyzchiva is highly similar to Stelara, which was approved in the EU in 2009.
Stay updated with breaking news from Static Physician. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The biosimilar Pyzchiva is highly similar to Stelara, which was approved in the EU in 2009.
Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.
Results of several clinical trials demonstrated the superior efficacy of risankizumab compared with apremilast or placebo.
This new research demonstrated that when TNF-inhibition is effective, a shift to brodalumab treatment may be useful in suppression of psoriasis and improvement of patients’ quality of life.
Patients on risankizumab also reported greater satisfaction with treatment for moderate plaque psoriasis.